Physician profile
Mena Abrahim
NPI 1457645707
$3,374.02
in general payments reported to CMS, 2019-2025
27 companies · $849 in 2025
The $849 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $137 · 2021: $195 · 2022: $370 · 2023: $603 · 2024: $604 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.40 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $759.01 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $468.17 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $408.84 | 2022-2025 | |
| Optinose US, INC. | $216.99 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $197.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $151.59 | 2019-2025 | Nucala, Arexvy |
| Biocomposites INC | $143.18 | 2025 | Stimulan |
| Csl Behring | $125.68 | 2019-2025 | Haegarda, Hizentra |
| Medtronic, INC. | $107.22 | 2021-2025 | Propel, Stealthstation S8 Platform |
| Takeda Pharmaceuticals U.S.A., INC. | $103.85 | 2022-2025 | Cuvitru |
| Intersect Ent, INC. | $97.94 | 2021 | |
| Stryker Corporation | $88.39 | 2019 | |
| Alk-Abello, INC | $81.88 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Novartis Pharmaceuticals Corporation | $75.21 | 2019-2023 | |
| Grifols USA, LLC | $59.78 | 2022-2025 | Xembify |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| Acclarent, INC | $45.78 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.79 | 2019-2023 | |
| Kaleo, INC. | $26.79 | 2019-2020 | |
| Lilly USA, LLC | $21.26 | 2024 | Ebglyss |
| Smith+Nephew, INC. | $21.05 | 2019 | |
| Mimedx Group, INC. | $18.69 | 2025 | |
| Incyte Corporation | $13.81 | 2024 | Opzelura |
| Shire North American Group INC | $13.77 | 2019 | |
| Olympus America INC. | $12.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.14 | 2025 | Voquezna |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mena Abrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.